Literature DB >> 10593626

Persistence of depressive symptoms and cardiovascular death among patients with affective disorder.

W Coryell1, C Turvey, A Leon, J D Maser, D Solomon, J Endicott, T Mueller, M Keller.   

Abstract

OBJECTIVE: Studies of both community and clinical samples have associated depressive symptoms with risks for subsequent cardiovascular morbidity and mortality. Because the physiological mechanisms thought to underlie this link would be cumulative in their effects, the following analyses tested the prediction that risks for cardiovascular death would increase in proportion to the persistence of depressive symptoms in a long-term follow-up.
METHODS: Baseline assessment was performed as patients sought treatment for major depressive disorder, mania, or schizo-affective disorder. Follow-up evaluations occurred semiannually for the next 5 years and annually thereafter. The 903 patients described, observed for a mean of 11.0 years (SD = 5.2 years), were divided into thirds according to the proportion of follow-up weeks in episodes of major depressive disorder, schizoaffective disorder, or intermittent depressive disorder. The resulting groups were then compared by cumulative risks of cardiovascular death.
RESULTS: Patients whose depressive symptoms were the most persistent were no more likely to die of cardiovascular causes than were those with the fewest weeks ill. A regression analysis showed that older age and the presence of cardiovascular disease at baseline, but not the subsequent chronicity of depressive symptoms, predicted cardiovascular death.
CONCLUSIONS: The physiological concomitants of depressive illness apparently do not promote cardiovascular mortality in a cumulative manner. Efforts should be directed toward identification of risk factors common to both lifetime depressive symptoms and cardiovascular morbidity.

Entities:  

Mesh:

Year:  1999        PMID: 10593626     DOI: 10.1097/00006842-199911000-00006

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  5 in total

1.  Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder.

Authors:  Jess G Fiedorowicz; David A Solomon; Jean Endicott; Andrew C Leon; Chunshan Li; John P Rice; William H Coryell
Journal:  Psychosom Med       Date:  2009-06-26       Impact factor: 4.312

2.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

3.  Hostility may explain the association between depressive mood and mortality: evidence from the French GAZEL cohort study.

Authors:  Cédric Lemogne; Hermann Nabi; Marie Zins; Sylvaine Cordier; Pierre Ducimetière; Marcel Goldberg; Silla M Consoli
Journal:  Psychother Psychosom       Date:  2010-02-20       Impact factor: 17.659

4.  Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study.

Authors:  Jess G Fiedorowicz; William H Coryell; John P Rice; Lois L Warren; William G Haynes
Journal:  Psychother Psychosom       Date:  2012-05-11       Impact factor: 17.659

Review 5.  Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders.

Authors:  Benjamin I Goldstein; Bernhard T Baune; David J Bond; Pao-Huan Chen; Lisa Eyler; Andrea Fagiolini; Fabiano Gomes; Tomas Hajek; Jessica Hatch; Susan L McElroy; Roger S McIntyre; Miguel Prieto; Louisa G Sylvia; Shang-Ying Tsai; Andrew Kcomt; Jess G Fiedorowicz
Journal:  Bipolar Disord       Date:  2020-06-08       Impact factor: 6.744

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.